ALZN Share Price Performance
US$2.36
-12.40 (-84.01%)
80.3% undervalued intrinsic discount
US$12.00
Fair Value
Price US$2.36
jacopo22295 US$12.00
Fair ValueUS$12.00
Share PriceUS$2.36
80.3% undervalued intrinsic discount
Alzamend Neuro, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
ALZN Community Narratives
JA
Fair Value US$12 80.3% undervalued intrinsic discount
Alzamend Neuro's Novel Lithium Formulation Will Target Major Mental Health Challenges
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Alzamend Neuro's Novel Lithium Formulation Will Target Major Mental Health Challenges
Catalysts AL001 : a novel lithium formulation targeting Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder (MDD), and PTSD. Phase II studies show promising safety/efficacy, with trials ongoing as of 2025.
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
JA
US$12
80.3% undervalued intrinsic discount
jacopo22295 Fair Value
Revenue growth
N/A
Profit Margin
20.86%
Future PE
29.37x
Share price in 2030
US$0
Snowflake Analysis
Alzamend Neuro, Inc. Key Details
About ALZN
- Founded
- 2016
- Employees
- 6
- CEO
- WebsiteView website
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
